DCE-MRI detects early vascular response in breast tumor xenografts following anti-DR5 Therapy

Hyunki Kim, Karri D. Folks, Lingling Guo, Cecil R. Stockard, Naomi S. Fineberg, William E. Grizzle, James F. George, Donald J. Buchsbaum, Desiree E. Morgan, Kurt R. Zinn

Research output: Contribution to journalArticlepeer-review

21 Scopus citations

Abstract

Purpose: Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) measured the early vascular changes after administration of TRA-8, bevacizumab, or TRA-8 combined with bevacizumab in breast tumor xenografts. Procedures: Groups 1-4 of nude mice bearing human breast carcinoma were injected with phosphate-buffered saline, TRA-8, bevacizumab, and TRA-8 + bevacizumab on day 0, respectively. DCE-MRI was performed on days 0, 1, 2, and 3, and thereafter tumors were collected for terminal deoxynucleotidyl transferase-mediated dUT nick end labeling and CD31 staining. Results: DCE-MRI measured a significant K trans change within 3 days after TRA-8 therapy that correlated with tumor growth arrest, which was not shown with statistical significance by histopathology at these early time points posttreatment. The K trans changes followed quadratic polynomial curves. Conclusion: DCE-MRI detected significantly lower K trans levels in breast tumor xenografts following TRA-8 monotherapy or combined therapy with bevacizumab.

Original languageEnglish
Pages (from-to)94-103
Number of pages10
JournalMolecular Imaging and Biology
Volume13
Issue number1
DOIs
StatePublished - Feb 2011
Externally publishedYes

Keywords

  • Bevacizumab
  • Breast cancer
  • DCE-MRI
  • DR5
  • Novel biomarker
  • Reference region model
  • TRA-8
  • TRAIL

Fingerprint

Dive into the research topics of 'DCE-MRI detects early vascular response in breast tumor xenografts following anti-DR5 Therapy'. Together they form a unique fingerprint.

Cite this